8 search results found
- June 22, 2020 | MIT News Office
Experimental peptide targets Covid-19
- March 27, 2020 | MIT News Office
An experimental peptide could block Covid-19
-
2023-Japan-Decoy Therapeutics
Broad-acting peptide conjugate antiviral platform -
4.28.23-Korea-Decoy-Therapeutics
Broad-acting peptide conjugate antiviral platform -
12.7.2022-Demo Day-Decoy Therapeutics
Broad-acting Peptide Conjugate Antiviral Platform
Barbara Hibner; Co-Founder and CSO, Decoy Therapeutics
-
Decoy Therapeutics Inc.
Cambridge, MAThe 21st century is experiencing epidemics and pandemics with increasing frequency, and the world needs new tools to combat these diseases. Decoy's platform engineers new pan-viral drugs that address both existing and new zoonotic viral threats. Our lead antiviral nasal spray has demonstrated... MoreKeywords:
-
Synthetic Biology Workshop 2017 - Lightning Talks
Lightning Talks featuring startups: Enbiotix, Ginkgo Bioworks, ManusBio, Glympse Bio, BioDevek, Asimov, and BioBuilder.
-
Synthetic Biology Workshop 2017 - Academic Keynote - Innovations in Synthetic Biology
James J. Collins, Termeer Professor of Medical Engineering & Science, MIT & co-founder of Enbiotix, Synlogic, and multiple other startups fostered in the Collins lab, including Sample6.
